Support IPC Subscribe  Contact Us  Privacy Statement
 twitter facebook LinkedIn YouTube
Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

About the International Psoriasis Council

The International Psoriasis Council (IPC) is a community of physician experts working to improve the health of people with psoriasis around the world.

 

Answering the call from the World Health Organization to train physicians to better care for people with psoriasis, IPC focuses helping dermatologists build expertise in psoriasis management.

 

To this end, IPC harnesses the collective expertise of its 100+ physicians to educate other physicians on the range of topics related to psoriasis management. Courses are presented live, via webinar or video on-demand. To reinforce its psoriasis curriculum, IPC publishes resources, tools and information available at no-cost to clinicians. All of IPC educational offerings are developed and presented by IPC Board Members and IPC Councilors, who are all recognized as key opinion leaders in the field of psoriasis.

 

Additionally, IPC conducts research in areas important to improving psoriasis care overall. These include developing a global epidemiological resource on psoriasis, reconsidering how disease severity is measured, and publishing a consensus statement on the use of biosimilars for the treatment of psoriasis.

 

Founded in 2004 as a US-based, non-profit organization, IPC is guided by a board of directors and supported day-to-day by its staff of non-profit leaders.



Our Vision: a world free of psoriasis.

We believe that psoriasis patients, no matter where they live in the world, no matter how complex their symptoms, should have access to the best care available to them, and that ultimately a world without psoriasis is possible.

Our Mission is to improve the care of people with psoriasis worldwide, through education, research and advocacy. 

About IPC

The IPC Impact

  • Trained 1,900 people in Latin America, Europe and the Middle East to care for psoriasis patients using the latest technologies

    •
  • Trained another 1,000 clinicians via IPC online continuing medical education programs

    •
  • Provided psoriasis resources, tools and information to 23,000 professionals

    • About IPC

    Our Strategic Plan

    IPC's plan for advancing  knowledge and enhancing  care for patients with psoriasis.

    READ MORE

    About IPC

    2019 Annual Report

    Improving psoriasis care worldwide

     

    READ REPORT
     

    Latest news

    Commentary: Genetic studies suggest that inflammatory skin diseases increase the risk of COVID-19.
    February 08, 2021
    Professor Francesca Capon provides a commentary An article recently published in the Journal of Allergy and Clinical Immunology1 suggests that diseases such as psoriasis and atopic dermatitis increase the risk of COVID-19 by approximately 50%.
    In the Lab with IPC Councilor Nicole Ward
    February 03, 2021
    Dr. Ward is a Professor of Dermatology and Neurosciences at Case Western Reserve University and University Hospitals Case Medical Center in Cleveland, Ohio. She has spent the past 16 years developing mouse models to help identify the cellular and molecular mechanisms underlying inflammatory skin disease and its associated comorbidities.
    Commentary: Cytokine inhibitors have a low prevalence of SARS-CoV-2 seroconversion
    February 02, 2021
    n a recent publication in Nature Communications1 a team from Friedrich-Alexander University in Germany described their findings from a cross-sectional population cohort study on the prevalence of anti-SARS-CoV-2 immunoglobulin G (IgG) in patients with chronic immune-mediated inflammatory diseases (IMIDs) on cytokine-blocking treatments. This patient cohort was compared against subjects with IMIDs, not on cytokine inhibitors, health care workers, and healthy controls. The findings from this study showed that patients with IMID on cytokine inhibitors had a lower prevalence of anti-SARS-CoV-2 IgG response compared to the other three cohorts. To assess whether this could be accounted for by differences in social exposure between the groups, the investigators assessed exposure risk variables in the four groups and found those to be similar between the two IMID groups and less than that of health care workers.
    Introducing the IPC Academy Online
    January 28, 2021
    IPC Academy Online, a free online learning platform, has been designed to provide expert insight, timely research, and practical information to dermatologists anywhere in the world to improve the care of psoriasis patients.
      More News

     

    Advancing Knowledge. Enhancing Care.

    		 Support Our Work

    IPC's mission is to advance the care of people with psoriasis worldwide, through education, research and advocacy.
    IPC is not in any way engaged in the practice of medicine or acting as a physician or health care professional or provider. The information IPC publishes is not intended as a substitute for the exercise of professional medical judgement by a health care provider following examination of a patient's condition. The ultimate responsibility for a patient's diagnosis or medical treatment rests with the patient's health care provider.
    International Psoriasis Council

    1034 S. Brentwood Blvd., Suite 600,
    St. Louis, MO USA 63117

    Tel (972) 861-0503     Fax (214) 242-3391
    email info@psoriasiscouncil.org

    © 2020 International Psoriasis Council. All Rights Reserved.

    We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
    OK